Arthur He CFA
Stock Analyst at H.C. Wainwright
(4.86)
# 332
Out of 4,670 analysts
140
Total ratings
57.8%
Success rate
36.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arthur He CFA
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMA ImageneBio | Initiated Coverage: Buy | $28 | $5.51 | +408.17% | 1 | Aug 21, 2026 | |
| NKTR Nektar Therapeutics | Maintained: Buy | $185 | $74.02 | +149.93% | 19 | Aug 17, 2026 | |
| TSX: MSCL Satellos Bioscience Inc. | Maintained: Buy | $24.79 | $13.80 | +79.63% | 14 | Aug 17, 2026 | |
| VERA Vera Therapeutics | Reiterated: Buy | $125 → $90 | $32.28 | +178.85% | 13 | Aug 12, 2026 | |
| JBIO Jade Biosciences | Maintained: Buy | $55 | $21.34 | +157.73% | 6 | Aug 11, 2026 | |
| SLDB Solid Biosciences | Maintained: Buy | $25 | $9.30 | +168.82% | 21 | Aug 10, 2026 | |
| PRME Prime Medicine | Maintained: Buy | $8 | $3.39 | +135.99% | 18 | Aug 10, 2026 | |
| ADAG Adagene | Reiterated: Buy | $7 | $4.01 | +74.56% | 18 | Apr 7, 2026 | |
| AUPH Aurinia Pharmaceuticals | Reiterated: Buy | $17 | $16.65 | +2.10% | 3 | Feb 27, 2026 | |
| BCAB BioAtla | Reiterated: Hold | n/a | $3.18 | n/a | 15 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.027 | n/a | 8 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $22.82 | n/a | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $27.00 → $35.00 | $31.44 | n/a | 3 | Apr 3, 2023 |
ImageneBio
Aug 21, 2026
Initiated Coverage: Buy
Price Target: $28
Current: $5.51
Upside: +408.17%
Nektar Therapeutics
Aug 17, 2026
Maintained: Buy
Price Target: $185
Current: $74.02
Upside: +149.93%
Satellos Bioscience Inc.
Aug 17, 2026
Maintained: Buy
Price Target: $24.79
Current: $13.80
Upside: +79.63%
Vera Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: $125 → $90
Current: $32.28
Upside: +178.85%
Jade Biosciences
Aug 11, 2026
Maintained: Buy
Price Target: $55
Current: $21.34
Upside: +157.73%
Solid Biosciences
Aug 10, 2026
Maintained: Buy
Price Target: $25
Current: $9.30
Upside: +168.82%
Prime Medicine
Aug 10, 2026
Maintained: Buy
Price Target: $8
Current: $3.39
Upside: +135.99%
Adagene
Apr 7, 2026
Reiterated: Buy
Price Target: $7
Current: $4.01
Upside: +74.56%
Aurinia Pharmaceuticals
Feb 27, 2026
Reiterated: Buy
Price Target: $17
Current: $16.65
Upside: +2.10%
BioAtla
Aug 11, 2025
Reiterated: Hold
Price Target: n/a
Current: $3.18
Upside: n/a
Jul 29, 2025
Downgraded: Hold
Price Target: n/a
Current: $0.027
Upside: n/a
Jun 21, 2024
Maintained: Buy
Price Target: n/a
Current: $22.82
Upside: n/a
Apr 3, 2023
Maintained: Buy
Price Target: $27.00 → $35.00
Current: $31.44
Upside: n/a